News - OBI Pharma 台灣浩鼎

2017.Jul.11

未分類

Corporate

Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

2017.Jun.01

未分類

Corporate

OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

2017.Jan.25

未分類

Corporate

China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study

2017.Jan.20

未分類

Corporate

OBI Pharma holds EOP2 meeting with US FDA

2017.Jan.10

未分類

Corporate

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.

2016.Nov.30

未分類

Award & Certification

OBI Pharma Awarded Level-A Recognition for TIPS Management

2016.Nov.23

未分類

Corporate

OBI Pharma Granted OBI 833 Patents for Taiwan and Australia

2016.Oct.26

未分類

Corporate

OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

2016.Sep.06

未分類

Corporate

Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine

2016.Sep.06

未分類

Corporate

OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

Announcements

Latest announcements

Events

Latest events